Compare Gilead Sciences, Inc. (GILD) vs iShares MSCI India ETF (INDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs iShares MSCI India ETF — how do they compare? Gilead Sciences, Inc. trades at $135.66 (market cap $163.51B), while iShares MSCI India ETF trades at $48.71. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while iShares MSCI India ETF pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, iShares MSCI India ETF nearer its low. Which is the better fit depends on your goals.
| GILD | INDA | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $155.80 | $55.29 |
52-Week Low | $108.22 | $45.42 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
INDA, the iShares MSCI India ETF, trades at $48.71 with minimal daily movement (-0.04%). Technical indicators show a bearish trend with moving averages signaling caution, though RSI suggests potential oversold conditions. The ETF faces mixed sentiment as India's economy grows at 7.8% (CNBC, 2026-06-05) while navigating AI adoption challenges and geopolitical risks. Recent news highlights India's position as the world's fastest-growing large economy with ongoing comparisons to other emerging market ETFs.
The outlook for INDA balances strong economic growth fundamentals against near-term headwinds including foreign investor outflows and sector-specific pressures. Investment opportunity lies in India's structural growth story, while risks include Middle East tensions impacting inflation and currency stability. Analyst views remain divided with some seeing value in the ETF's sector composition and growth potential despite recent underperformance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →
